[ad_1]
A Cuban biotechnology company is employing to prove the effectiveness of Cuban treatment for lung cancer, with a view to its potential use on American patients, within the framework of a remarkable collaboration in the field of medical research between two hostile countries for decades.
This treatment is still in the experimental phase and is called Simafax-EGF.
"This is an additional weapon in the fight against cancer that can be used in conjunction with other therapeutic weapons, such as chemotherapy," said Orestes Santos, a researcher at the Center for Disease Control. Molecular immunology in Havana.
The Roswell Park Cancer Center, based in the US city of Buffalo in 2015, signed a partnership agreement with the Cuban Institute during a mission in an American mission to Cuba.
The partnership aims to fund the development of treatments and to conduct new, more comprehensive and larger clinical trials in North America.
"The results of the first clinical trials are very encouraging," said Doug Plessinger, head of scientific development at Roswell Park Center. "We combine treatment with Simafax and immunotherapy.
Treatment, administered as a monthly dose in Cuban health centers since 2011, has been approved by the health authorities of Paraguay, Peru, Sri Lanka, Malaysia and Bosnia.
[ad_2]
Source link
